Market Research Industry Reports

Heart Transplant Rejection - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Heart Transplant Rejection - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.

Table of ContentsTable of Contents 2List of Tables

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Heart Transplant Rejection - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Heart Transplant Rejection (Immunology)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heart Transplant Rejection (Immunology) pipeline guide
The guide covers therapeutics under Development by Companies /Universities /Institutes,
Heart Transplant Rejection - Pipeline Review, H1 2018 Reference Code: GMDHC10549IDBPublication Date: June 2018

Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
Heart Transplant Rejection - Pipeline Review, H1 2018 Reference Code: GMDHC10549IDBPublication Date: June 2018 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heart Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heart Transplant Rejection - Overview
Heart Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Heart Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heart Transplant Rejection - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Heat Biologics Inc
Noxxon Pharma AG
TxCell SA
Heart Transplant Rejection - Drug Profiles
2C-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2521780 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2553627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emapticap pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENTX-MS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTX-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heart Transplant Rejection - Dormant Projects
Heart Transplant Rejection - Product Development Milestones
Featured News & Press Releases
Sep 27, 2017: Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma to Advance PTX-15 Fusion Protein
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Heart Transplant Rejection, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Heart Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2018
Heart Transplant Rejection - Pipeline by Heat Biologics Inc, H1 2018
Heart Transplant Rejection - Pipeline by Noxxon Pharma AG, H1 2018
Heart Transplant Rejection - Pipeline by TxCell SA, H1 2018
Heart Transplant Rejection - Dormant Projects, H1 2018

List Of Figures

List of Figures
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

Heart Transplant Rejection - Pipeline Review, H1 2018

Heart Transplant Rejection - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the

USD 2000View Report

Total Artificial Heart - Medical Devices Pipeline Assessment, 2018

Total Artificial Heart - Medical Devices Pipeline Assessment, 2018GlobalDatas Medical Devices sector report, Total Artificial Heart - Medical Devices Pipeline Assessment, 2018 provides an overview of Total Artificial Heart currently

USD 2500View Report

Lung Transplant Rejection - Pipeline Review, H1 2018

Lung Transplant Rejection - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the

USD 2000View Report

Kidney Transplant Rejection Pipeline Review H1 2018

Kidney Transplant Rejection - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the

USD 2000View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Jun 2018
No. of Pages :32
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube